[Role of natural killer cells in the antimetastatic effect of defibrinogenation with batroxobin]. 1987

M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani

The antimetastatic effects of defibrinogenation with batroxobin were investigated in normal mice and in mice with depressed or activated natural killer (NK) cell activity. Batroxobin inhibited the formation of lung metastases after intravenous inoculation of the F10 subline of B16 melanoma. Inhibition of NK activity by treatment of mice with anti-asialo GM1 antibody abrogated the antimetastatic effects of Batroxobin. Conversely, augmentation of NK cell activity by poly I:C plus treatment with batroxobin produced additive antimetastatic effects. Studies on the mechanism of interaction between Batroxobin and NK cells revealed that Batroxobin treatment did not affect splenic NK activity in vitro. From these data, it was found that the antimetastatic effects of batroxobin are dependent on the level of NK activity in the host.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D011070 Poly I-C Interferon inducer consisting of a synthetic, mismatched double-stranded RNA. The polymer is made of one strand each of polyinosinic acid and polycytidylic acid. Poly(I-C),Poly(rI).Poly(rC),Polyinosinic-Polycytidylic Acid,Polyinosinic-Polycytidylic Acid (High MW),Polyriboinosinic-Polyribocytidylic Acid,Polyribose Inosin-Cytidil,Inosin-Cytidil, Polyribose,Poly I C,Polyinosinic Polycytidylic Acid,Polyriboinosinic Polyribocytidylic Acid,Polyribose Inosin Cytidil
D012103 Batroxobin A proteolytic enzyme obtained from the venom of fer-de-lance (BOTHROPS ATROX). It is used as a plasma clotting agent for fibrinogen and for the detection of fibrinogen degradation products. The presence of heparin does not interfere with the clotting test. Hemocoagulase is a mixture containing batroxobin and factor X activator. EC 3.4.21.-. Defibrol,Hemocoagulase,Defibrase,Reptilase,Reptilase-DEF,Reptilase DEF
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
October 1985, Thrombosis research,
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
January 1988, Folia haematologica (Leipzig, Germany : 1928),
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
April 2000, Immunological reviews,
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
September 1983, Thrombosis research,
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
August 2020, Cancer science,
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
January 2011, Journal of biomedicine & biotechnology,
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
October 2015, Periodontology 2000,
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
October 1995, Current opinion in immunology,
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
September 1988, The American review of respiratory disease,
M Shibuya, and S Kawachi, and A Aoyama, and A Murata, and M Baba, and K Hirata, and M Ohtsuka, and M Matsusaka, and T Yano, and H Niitani
January 1993, Natural immunity,
Copied contents to your clipboard!